Shuai Song1, Dong Chang1, Yong Cui1, Jian Hu1, Min Gong1, Kai Ma2, Fang Ding3, Zhi-Hua Liu3, Tian-You Wang1. 1. Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University Beijing, China. 2. Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University Qingdao, China. 3. State Key Laboratory of Molecular Oncology, Cancer institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, China.
Abstract
BACKGROUND: Subcutaneous xenograft is a common method to establish animal models of human esophageal squamous cell carcinoma (ESCC). However, the growth microenvironment of transplanted tumors is different from primary tumors. Orthotopic implantation models can provide more biologically relevant context in which to study the disease. So far, an orthotopic implantation model of ESCC has rarely been reported. METHODS: The human ESCC cell line KYSE30 was transfected with pLVX-Luciferase plasmids. KYSE30-Luciferase cells were isolated and injected into the flanks of nude mice to develop a subcutaneous tumor. An orthotopic implantation model was established using the fragments derived from the subcutaneous tumor. Fluorescence imaging was used to observe the development of the orthotopic implanted tumor. Hematoxylin and eosin staining was performed to evaluate the invasion and metastasis of the tumor. RESULTS: KYSE30 cells were successfully transfected with pLVX-Luciferase plasmids. A primary tumor was developed in all mice. The mice experienced body weight loss. The implanted tumor infiltrated into the esophageal muscularis propria. However, neither distant organ nor lymph node metastasis was found. The progression of the primary tumor was monitored by in vivo fluorescence imaging. CONCLUSION: The orthotopic implantation model can be established by sewing the fragments of human ESCC to the abdominal esophagus of a nude mouse. The progression of an orthotopic implantation tumor can be monitored in real time by in vivo fluorescence imaging.
BACKGROUND: Subcutaneous xenograft is a common method to establish animal models of humanesophageal squamous cell carcinoma (ESCC). However, the growth microenvironment of transplanted tumors is different from primary tumors. Orthotopic implantation models can provide more biologically relevant context in which to study the disease. So far, an orthotopic implantation model of ESCC has rarely been reported. METHODS: The human ESCC cell line KYSE30 was transfected with pLVX-Luciferase plasmids. KYSE30-Luciferase cells were isolated and injected into the flanks of nude mice to develop a subcutaneous tumor. An orthotopic implantation model was established using the fragments derived from the subcutaneous tumor. Fluorescence imaging was used to observe the development of the orthotopic implanted tumor. Hematoxylin and eosin staining was performed to evaluate the invasion and metastasis of the tumor. RESULTS: KYSE30 cells were successfully transfected with pLVX-Luciferase plasmids. A primary tumor was developed in all mice. The mice experienced body weight loss. The implanted tumor infiltrated into the esophageal muscularis propria. However, neither distant organ nor lymph node metastasis was found. The progression of the primary tumor was monitored by in vivo fluorescence imaging. CONCLUSION: The orthotopic implantation model can be established by sewing the fragments of human ESCC to the abdominal esophagus of a nude mouse. The progression of an orthotopic implantation tumor can be monitored in real time by in vivo fluorescence imaging.
Authors: T Furihata; T Sakai; H Kawamata; F Omotehara; Y Shinagawa; J Imura; Y Ueda; K Kubota; T Fujimori Journal: Int J Oncol Date: 2001-11 Impact factor: 5.650
Authors: Stephanie J Gros; Thorsten Dohrmann; Kersten Peldschus; Paulus G Schurr; Jussuf T Kaifi; Tatyana Kalinina; Uta Reichelt; Oliver Mann; Tim G Strate; Gerhard Adam; Robert M Hoffman; Jakob R Izbicki Journal: Int J Cancer Date: 2010-06-01 Impact factor: 7.396
Authors: Lai Nar Tung; Senchuan Song; Kin Tak Chan; Mei Yuk Choi; Ho Yu Lam; Chung Man Chan; Zhiyong Chen; Hector K Wang; Hoi Ting Leung; Simon Law; Yanmin Huang; Huacan Song; Nikki P Lee Journal: Cancer Res Treat Date: 2018-01-24 Impact factor: 4.679